Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

doi:10.1126/science.aan3706

. 2018 Jan 5;359(6371):91-97.

doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy^{1

2

3}, Emmanuelle Le Chatelier⁴, Lisa Derosa^{1

2

3}, Connie P M Duong^{1

2

5}, Maryam Tidjani Alou^{1

2

3}, Romain Daillère^{1

2

3}, Aurélie Fluckiger^{1

2

5}, Meriem Messaoudene^{1

2}, Conrad Rauber^{1

2

3}, Maria P Roberti^{1

2

5}, Marine Fidelle^{1

3

5}, Caroline Flament^{1

2

5}, Vichnou Poirier-Colame^{1

2

5}, Paule Opolon⁶, Christophe Klein⁷, Kristina Iribarren^{8

9

10

11

12}, Laura Mondragón^{8

9

10

11

12}, Nicolas Jacquelot^{1

2

3}, Bo Qu^{1

2

3}, Gladys Ferrere^{1

2

3}, Céline Clémenson^{1

13}, Laura Mezquita^{1

14}, Jordi Remon Masip^{1

14}, Charles Naltet¹⁵, Solenn Brosseau¹⁵, Coureche Kaderbhai¹⁶, Corentin Richard¹⁶, Hira Rizvi¹⁷, Florence Levenez⁴, Nathalie Galleron⁴, Benoit Quinquis⁴, Nicolas Pons⁴, Bernhard Ryffel¹⁸, Véronique Minard-Colin^{1

19}, Patrick Gonin^{1

20}, Jean-Charles Soria^{1

14}, Eric Deutsch^{1

13}, Yohann Loriot^{1

3

14}, François Ghiringhelli¹⁶, Gérard Zalcman¹⁵, François Goldwasser^{9

21

22}, Bernard Escudier^{1

14

23}, Matthew D Hellmann^{24

25}, Alexander Eggermont^{1

2

14}, Didier Raoult²⁶, Laurence Albiges^{1

3

14}, Guido Kroemer^{27

9

10

11

12

28

29}, Laurence Zitvogel^{30

2

3

5}

Affiliations

¹ Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
² Institut National de la Santé et de la Recherche Medicale (INSERM) U1015 and Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.
³ Univ. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
⁴ MGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
⁵ Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
⁶ Gustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, France.
⁷ Centre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Sorbonne Paris Cité, UMRS 1138, Université Pierre et Marie Curie Université Paris 06, Sorbonne Universités, Paris, France.
⁸ Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
⁹ Paris Descartes University, Sorbonne Paris Cité, Paris, France.
¹⁰ Equipe 11 Labellisée-Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
¹¹ INSERM U1138, Paris, France.
¹² Université Pierre et Marie Curie, Paris, France.
¹³ Department of Radiation Oncology, INSERM U1030, and Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805 Villejuif, France.
¹⁴ Department of Medical Oncology, Gustave Roussy, Villejuif, France.
¹⁵ Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.
¹⁶ Department of Medical Oncology, Center GF Leclerc, Dijon, France.
¹⁷ Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁸ Molecular Immunology and Embryology, UMR 7355, CNRS, University of Orleans, Orléans, France.
¹⁹ Department of Pediatric Oncology, GRCC, Villejuif, France.
²⁰ Preclinical Research Platform, GRCC, Villejuif, France.
²¹ Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
²² Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
²³ INSERM U981, GRCC, Villejuif, France.
²⁴ Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁵ Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
²⁶ URMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, 13005 Marseille, France.
²⁷ Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
²⁸ Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
²⁹ Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.
³⁰ Gustave Roussy Cancer Campus (GRCC), Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.

PMID: 29097494
DOI: 10.1126/science.aan3706

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al. Science. 2018.

. 2018 Jan 5;359(6371):91-97.

doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

Authors

Affiliations

¹ Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
² Institut National de la Santé et de la Recherche Medicale (INSERM) U1015 and Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.
³ Univ. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
⁴ MGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
⁵ Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
⁶ Gustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, France.
⁷ Centre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Sorbonne Paris Cité, UMRS 1138, Université Pierre et Marie Curie Université Paris 06, Sorbonne Universités, Paris, France.
⁸ Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
⁹ Paris Descartes University, Sorbonne Paris Cité, Paris, France.
¹⁰ Equipe 11 Labellisée-Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
¹¹ INSERM U1138, Paris, France.
¹² Université Pierre et Marie Curie, Paris, France.
¹³ Department of Radiation Oncology, INSERM U1030, and Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805 Villejuif, France.
¹⁴ Department of Medical Oncology, Gustave Roussy, Villejuif, France.
¹⁵ Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.
¹⁶ Department of Medical Oncology, Center GF Leclerc, Dijon, France.
¹⁷ Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁸ Molecular Immunology and Embryology, UMR 7355, CNRS, University of Orleans, Orléans, France.
¹⁹ Department of Pediatric Oncology, GRCC, Villejuif, France.
²⁰ Preclinical Research Platform, GRCC, Villejuif, France.
²¹ Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
²² Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
²³ INSERM U981, GRCC, Villejuif, France.
²⁴ Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁵ Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
²⁶ URMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, 13005 Marseille, France.
²⁷ Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
²⁸ Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
²⁹ Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.
³⁰ Gustave Roussy Cancer Campus (GRCC), Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.

PMID: 29097494
DOI: 10.1126/science.aan3706

Abstract

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so. Metagenomics of patient stool samples at diagnosis revealed correlations between clinical responses to ICIs and the relative abundance of Akkermansia muciniphila Oral supplementation with A. muciniphila after FMT with nonresponder feces restored the efficacy of PD-1 blockade in an interleukin-12-dependent manner by increasing the recruitment of CCR9⁺CXCR3⁺CD4⁺ T lymphocytes into mouse tumor beds.

PubMed Disclaimer

Comment in

Immunotherapy: Gut bacteria modulate responses to PD-1 blockade.
Killock D. Killock D. Nat Rev Clin Oncol. 2018 Jan;15(1):6-7. doi: 10.1038/nrclinonc.2017.182. Epub 2017 Nov 21. Nat Rev Clin Oncol. 2018. PMID: 29158588 No abstract available.
Precision medicine using microbiota.
Jobin C. Jobin C. Science. 2018 Jan 5;359(6371):32-34. doi: 10.1126/science.aar2946. Science. 2018. PMID: 29302001 No abstract available.
Anti-PD1 in the wonder-gut-land.
Vetizou M, Trinchieri G. Vetizou M, et al. Cell Res. 2018 Mar;28(3):263-264. doi: 10.1038/cr.2018.12. Epub 2018 Jan 16. Cell Res. 2018. PMID: 29336431 Free PMC article.
Microbiome: Gut microbiota sways response to cancer immunotherapy.
York A. York A. Nat Rev Microbiol. 2018 Mar;16(3):121. doi: 10.1038/nrmicro.2018.12. Epub 2018 Jan 22. Nat Rev Microbiol. 2018. PMID: 29355853 No abstract available.
Flora-ishing guts assist cancer immunotherapies.
Davis LS. Davis LS. Sci Immunol. 2018 Feb 2;3(20):eaat0813. doi: 10.1126/sciimmunol.aat0813. Sci Immunol. 2018. PMID: 29429981
Could Fecal Transplantation Become Part of PD-1-Based Immunotherapy, Due to Effects of the Intestinal Microbiome?
Biancheri P, Divekar D, Watson AJM. Biancheri P, et al. Gastroenterology. 2018 May;154(6):1845-1847. doi: 10.1053/j.gastro.2018.03.060. Epub 2018 Apr 1. Gastroenterology. 2018. PMID: 29614305 No abstract available.
Checkpoint Checkmate: Microbiota Modulation of Cancer Immunotherapy.
Keen EC, Crofts TS, Dantas G. Keen EC, et al. Clin Chem. 2018 Sep;64(9):1280-1283. doi: 10.1373/clinchem.2017.286229. Epub 2018 Apr 24. Clin Chem. 2018. PMID: 29691222 Free PMC article. No abstract available.
Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors.
Santoni M, Piva F, Conti A, Santoni A, Cimadamore A, Scarpelli M, Battelli N, Montironi R. Santoni M, et al. Eur Urol. 2018 Oct;74(4):521-522. doi: 10.1016/j.eururo.2018.05.033. Epub 2018 Jun 8. Eur Urol. 2018. PMID: 29891391 No abstract available.
Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy.
Liu K, Lu C. Liu K, et al. Transl Cancer Res. 2018 Jun;7(Suppl 5):S608-S610. doi: 10.21037/tcr.2018.05.37. Transl Cancer Res. 2018. PMID: 30443490 Free PMC article. No abstract available.
The microbiome influence.
Stower H. Stower H. Nat Med. 2018 Dec;24(12):1782. doi: 10.1038/s41591-018-0285-2. Nat Med. 2018. PMID: 30523317 No abstract available.
[Gut microbiome influences efficacy of immunotherapy].
de Nonneville A. de Nonneville A. Bull Cancer. 2019 Jan;106(1):10. doi: 10.1016/j.bulcan.2018.12.004. Epub 2019 Jan 11. Bull Cancer. 2019. PMID: 30642560 French. No abstract available.
Gut microbiome: a key player in cancer immunotherapy.
Shigematsu Y, Inamura K. Shigematsu Y, et al. Hepatobiliary Surg Nutr. 2018 Dec;7(6):479-480. doi: 10.21037/hbsn.2018.10.02. Hepatobiliary Surg Nutr. 2018. PMID: 30652093 Free PMC article. No abstract available.
The role of gut microbiota in immune checkpoint inhibitor therapy.
Yi M, Qin S, Chu Q, Wu K. Yi M, et al. Hepatobiliary Surg Nutr. 2018 Dec;7(6):481-483. doi: 10.21037/hbsn.2018.11.12. Hepatobiliary Surg Nutr. 2018. PMID: 30652094 Free PMC article. No abstract available.

Cited by

Cancer-induced systemic pre-conditioning of distant organs: building a niche for metastatic cells.
Rabas N, Ferreira RMM, Di Blasio S, Malanchi I. Rabas N, et al. Nat Rev Cancer. 2024 Oct 10. doi: 10.1038/s41568-024-00752-0. Online ahead of print. Nat Rev Cancer. 2024. PMID: 39390247 Review.
Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers.
Nejat Dehkordi A, Maddahi M, Vafa P, Ebrahimi N, Aref AR. Nejat Dehkordi A, et al. Clin Transl Oncol. 2024 Oct 8. doi: 10.1007/s12094-024-03742-8. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39377974 Review.
Hidden army within: Harnessing the microbiome to improve cancer treatment outcomes.
Messaritakis I, Vougiouklakis G, Koulouridi A, Agouridis AP, Spernovasilis N. Messaritakis I, et al. World J Clin Cases. 2024 Oct 6;12(28):6159-6164. doi: 10.12998/wjcc.v12.i28.6159. World J Clin Cases. 2024. PMID: 39371567 Free PMC article.
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.
Li Q, Geng S, Luo H, Wang W, Mo YQ, Luo Q, Wang L, Song GB, Sheng JP, Xu B. Li Q, et al. Signal Transduct Target Ther. 2024 Oct 7;9(1):266. doi: 10.1038/s41392-024-01953-7. Signal Transduct Target Ther. 2024. PMID: 39370455 Free PMC article. Review.
Gastrointestinal cancer resistance to treatment: the role of microbiota.
Kolahi Sadeghi L, Vahidian F, Eterafi M, Safarzadeh E. Kolahi Sadeghi L, et al. Infect Agent Cancer. 2024 Oct 5;19(1):50. doi: 10.1186/s13027-024-00605-3. Infect Agent Cancer. 2024. PMID: 39369252 Free PMC article. Review.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Affiliations

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Authors

Affiliations

Abstract

Comment in

Similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Abstract

Comment in

Similar articles

Cited by

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials